| Literature DB >> 27438024 |
Rakesh Ayer1, Kimiyo Kikuchi1, Mamata Ghimire2, Akira Shibanuma1, Madhab Raj Pant3, Krishna C Poudel4, Masamine Jimba1.
Abstract
INTRODUCTION: HIV-positive people's clinic attendance for medication pick-up is critical for successful HIV treatment. However, limited evidence exists on it especially in low-income settings such as Nepal. Moreover, the role of family support in clinic attendance remains under-explored. Therefore, this study was conducted to examine the association between perceived family support and regular clinic attendance and to assess factors associated with regular clinic attendance for antiretroviral pills pick-up among HIV-positive individuals in Nepal.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27438024 PMCID: PMC4954679 DOI: 10.1371/journal.pone.0159382
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
General characteristics of the participants.
| Characteristics | Overall | Regular attendants | Inconsistent attendants | p-value |
|---|---|---|---|---|
| n (%) | n (%) | |||
| 423 | 138 (32.6) | 285 (67.4) | ||
| 39.7 (9.5) | 40.7 (10.2) | 39.2 (9.1) | 0.127 | |
| Male | 202 (47.8) | 68 (49.3) | 134 (47.0) | 0.663 |
| Female | 221 (52.2) | 70 (50.7) | 151 (53.0) | |
| Yes | 282 (66.7) | 99 (71.7) | 183 (64.2) | 0.124 |
| No | 141 (33.3) | 39 (28.3) | 102 (35.8) | |
| Unemployed | 154 (36.4) | 52 (37.7) | 102 (35.8) | 0.705 |
| Employed | 269 (63.6) | 86 (62.3) | 183 (64.2) | |
| Urban | 277 (65.5) | 98 (71.0) | 179 (62.8) | 0.096 |
| Rural | 146 (34.5) | 40 (29.0) | 106 (37.2) | |
| Low(0–22) | 174 (41.2) | 38 (27.5) | 136 (47.7) | <0.001 |
| Moderate(23–26) | 105 (24.8) | 23 (16.7) | 82 (28.8) | |
| High(27–30) | 144 (34.0) | 77 (55.8) | 67 (23.5) | |
| Yes | 171 (40.4) | 66 (47.8) | 105 (36.8) | 0.031 |
| No | 252 (59.6) | 72 (52.2) | 180 (63.2) | |
| ≤60 minutes | 253 (59.8) | 94 (68.1) | 159 (55.8) | 0.015 |
| >60 minutes | 170 (40.2) | 44 (31.9) | 126 (44.2) | |
Health and HIV status related characteristics of the participants.
| Characteristics | Overall | Regular attendants | Inconsistent attendants | p-value |
|---|---|---|---|---|
| n (%) | n (%) | n (%) | ||
| Yes | 341 (80.6) | 105 (76.1) | 236 (82.8) | 0.101 |
| No | 82 (19.4) | 33 (23.9) | 49 (17.2) | |
| AZT | 58 (13.7) | 20 (14.5) | 38 (13.3) | 0.842 |
| AZT+3TC+NVP | 180 (42.6) | 62 (44.9) | 118 (41.4) | |
| TDF | 83 (19.6) | 25 (18.1) | 58 (20.4) | |
| TDF+3TC+NVP | 102 (24.1) | 31 (22.5) | 71 (24.9) | |
| Stage I | 72 (17.0) | 17 (12.3) | 55 (19.3) | 0.349 |
| Stage II | 99 (23.4) | 33 (24.0) | 66 (23.2) | |
| Stage III | 226 (53.4) | 79 (57.2) | 147 (51.6) | |
| Stage IV | 26 (6.2) | 9 (6.5) | 17 (5.9) | |
| Yes | 87 (20.6) | 24 (17.4) | 63 (22.1) | 0.261 |
| No | 336 (79.4) | 114 (82.6) | 222 (77.9) | |
| Excellent | 21 (4.9) | 14 (10.2) | 7 (2.5) | 0.001 |
| Very good | 103 (24.4) | 30 (21.7) | 73 (25.6) | |
| Good | 172 (40.7) | 46 (33.3) | 126 (44.2) | |
| Fair | 127 (30.0) | 48 (34.8) | 79 (27.7) | |
| Yes | 309 (73.1) | 122 (88.4) | 187 (65.6) | <0.001 |
| No | 114 (26.9) | 16 (11.6) | 98 (34.4) | |
| Yes | 266 (62.9) | 107 (77.5) | 159 (55.8) | <0.001 |
| No | 157 (37.1) | 31 (22.5) | 126 (44.2) | |
| Yes | 311 (73.5) | 114 (82.6) | 197 (69.1) | 0.003 |
| No | 112 (26.5) | 24 (17.4) | 88 (30.9) | |
a AZT- Zidovudine
b 3TC-Lamivudine
c EFV- Efavirenz
d NVP- Nevirapine
e TDF- Tenofovir.
Factors associated with regular clinic attendance for pills pick-up among the people living with HIV in Nepal.
| Unadjusted model | Adjusted model | |||
|---|---|---|---|---|
| Variables | OR | 95% CI | AOR | 95% CI |
| 1.01 | 0.99–1.03 | 1.01 | 0.98–1.04 | |
| Male | 1.00 | 1.00 | ||
| Female | 0.91 | 0.60–1.37 | 1.12 | 0.64–1.98 |
| Yes | 1.00 | 1.00 | ||
| No | 0.70 | 0.45–1.10 | 0.65 | 0.36–1.17 |
| Unemployed | 1.00 | 1.00 | ||
| Employed | 0.92 | 0.60–1.40 | 0.96 | 0.55–1.67 |
| Urban | 1.00 | 1.00 | ||
| Rural | 0.68 | 0.44–1.06 | 1.06 | 0.58–1.95 |
| ≤60 minutes | 1.00 | 1.00 | ||
| >60 minutes | 0.59 | 0.38–0.90 | 0.53 | 0.30–0.93 |
| Yes | 1.00 | 1.00 | ||
| No | 1.51 | 0.92–2.48 | 1.14 | 0.62–2.10 |
| AZT+3TC+EFV | 1.00 | 1.00 | ||
| AZT+3TC+NVP | 0.99 | 0.53–1.86 | 1.34 | 0.63–2.84 |
| TDF+3TC+EFV | 0.81 | 0.40–1.67 | 0.87 | 0.37–2.02 |
| TDF+3TC+NVP | 0.82 | 0.41–1.64 | 0.93 | 0.41–2.11 |
| Stage I | 1.00 | 1.00 | ||
| Stage II | 1.61 | 0.81–3.21 | 1.95 | 0.89–4.26 |
| Stage III & IV | 1.73 | 0.95–3.17 | 1.98 | 0.97–4.03 |
| Yes | 1.00 | 1.00 | ||
| No | 1.34 | 0.80–2.27 | 1.40 | 0.74–2.67 |
| Low(0–22) | 1.00 | 1.00 | ||
| Moderate(23–26) | 1.00 | 0.55–1.80 | 0.84 | 0.44–1.60 |
| High(27–30) | 4.11 | 2.52–6.68 | 3.98 | 2.29–6.92 |
| No | 1.00 | 1.00 | ||
| Yes | 1.57 | 1.04–2.37 | 1.68 | 1.00–2.82 |
| Excellent | 1.00 | 1.00 | ||
| Very good | 0.20 | 0.07–0.55 | 0.13 | 2. 0.04–0.44 |
| Good | 0.18 | 0.06–0.48 | 0.14 | 0.04–0.46 |
| Fair | 0.30 | 0.11–0.80 | 0.21 | 0.06–0.70 |
| No | 1.00 | 1.00 | ||
| Yes | 3.99 | 2.24–7.10 | 2.62 | 1.15–5.99 |
| No | 1.00 | 1.00 | ||
| Yes | 2.73 | 1.72–4.34 | 1.42 | 0.70–2.86 |
| No | 1.00 | 1.00 | ||
| Yes | 2.12 | 1.27–3.52 | 1.47 | 0.78–2.79 |
*p<0.05
**p<0.01
***P<0.001.